| 1 |
Leigh PN, Ray-chaudhuri K．Motor neuron disease[J]．J Neurol Neurosurg Psychiatry，1994，57(8):886-896.
|
| 2 |
冯凯，许贤豪，孟晓梅，等．运动神经元病的诊治进展[J]．中国神经免疫学和神经病学杂志，2006，13(1):57-59.
|
| 3 |
贾建平，陈生弟．神经病学[M].7版．北京：人民卫生出版社，2013：213-217.
|
| 4 |
National Institute of Neurological Disorders and Stroke(NINDS)．Motor Neuron Diseases Fact Sheet[EB/OL]．(2014-04-13)[2019-01-04]．
URL
|
| 5 |
王毅．渐冻人——肌萎缩侧索硬化症[J]．家庭医学(下)，2014，(10):8-10.
|
| 6 |
贾建平，陈生弟．神经病学[M].7版．北京：人民卫生出版社，2013：214.
|
| 7 |
Mandrioli J, Faglioni P, Nichelli P，et al.Amyotrophic lateral sclerosis：Prognostic indicators of survival[J]．Amyotroph Lateral Scler，2006，7(4):211-220.
|
| 8 |
康丽，胡芳芳，靳娇婷，等．肌萎缩侧索硬化症患者生存期的影响因素分析[J]．西安交通大学学报(医学版)，2018，39(5):639-643.
|
| 9 |
李晓光，刘明生，崔丽英．肌萎缩侧索硬化的临床分型、分期及病情评估[J]．协和医学杂志，2018，9(1):69-74.
|
| 10 |
陈璐，樊东升．肌萎缩侧索硬化症的自然病史和临床特征[J]．中华内科杂志，2014，53(9):752-754.
|
| 11 |
冀拓，樊东升．肌萎缩侧索硬化与环境因素关系的研究进展[J]．中华内科杂志，2018，57(8):607-609.
|
| 12 |
Rowland LP.How amyotrophic lateral sclerosis got its name：the clinical-pathologic genius of Jean-Martin Charcot[J]．Arch Neurol，2001，58(3):512-515.
|
| 13 |
Kelly EB.Encyclopedia of human genetics and disease[M]．Santa Barbara，California：Greenwood，2013：79-80.
|
| 14 |
Youngson, David BJ, Robert M．Encyclopedia of family health[M]．Tarrytown，NY：Marshall Cavendish，2004：1256.
|
| 15 |
Aebischer P, Kato AC.Playing defense against Lou Gehrig’s disease[J]．Sci Am，2007，297(5):86-93.
|
| 16 |
Song PP.The Ice Bucket Challenge：The public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseases[J]．Intractable Rare Dis Res，2014，3(3):94-96.
|
| 17 |
国家卫生健康委员会，科学技术部，工业和信息化部，等．关于公布第一批罕见病目录的通知(国卫医发〔2018〕10号)[EB/OL]．(2018-05-11)[2018-12-11]．
URL
|
| 18 |
GBD 2016 Motor Neuron Disease Collaborators.Global，regional，and national burden of motor neurondiseases 1990-2016：a systematic analysis for the GlobalBurden of Disease Study 2016[J]．Lancet Neurol，2018，17(12):1083-1097.
|
| 19 |
Liu X, He J, Gao FB，et al.The epidemiology and genetics of Amyotrophic lateral sclerosis in China[J]．Brain Res，2018，1693(Pt A):121-126.
|
| 20 |
Liu MS, Cui LY, Fan DS.Age at onset of amyotrophic lateral sclerosis in China[J]．Acta Neurol Scand，2014，129(3):163-167.
|
| 21 |
崔博，崔丽英．肌萎缩侧索硬化流行病学研究现状[J]．中华神经科杂志，2015，48(6):542-544.
|
| 22 |
Zhou S, Zhou Y, Qian S，et al.Amyotrophic lateral sclerosis in Beijing：Epidemiologic features and prognosis from 2010 to 2015[J]．Brain Behav，2018，8(11):e01131.
|
| 23 |
赵蕾，崔丽英，杜华，等．运动神经元病伴随尿便功能障碍的原因分析[J]．中华神经科杂志，2014，47(11):767-771.
|
| 24 |
王一凡，樊东升．肌萎缩侧索硬化的疼痛问题[J]．中国医学前沿杂志(电子版)，2015，(9):1-3.
|
| 25 |
Braun MM, Osecheck M, Joyce NC.Nutrition assessment and management in amyotrophic lateral sclerosis[J]．Phys Med Rehabil Clin N Am，2012，23(4):751-771.
|
| 26 |
李和平，张博爱，江泽，等．间歇经口至食管管饲对运动神经元病所致吞咽障碍患者营养状况及肺部感染的影响[J]．中华物理医学与康复杂志，2016，38(8):602-604.
|
| 27 |
孙梅影，丁卫江．肌萎缩侧索硬化夜间睡眠呼吸障碍的研究进展[J]．临床神经病学杂志，2014，27(1):76-77.
|
| 28 |
孙小英，丁岩，李存江．神经变性病相关睡眠呼吸暂停研究进展[J]．北京医学，2014，(10):836-838.
|
| 29 |
王芳，黄朝阳，丁岩，等．肌萎缩侧索硬化症患者睡眠障碍及睡眠呼吸障碍特点分析[J]．中国现代神经疾病杂志，2017，17(10):741-747.
|
| 30 |
Statland JM, Barohn RJ, McVey AL，et al.Patterns of weakness，classification of motor neuron disease，and clinical diagnosis of sporadic amyotrophic lateral sclerosis[J]．Neurol Clin，2015，33(4):735-748.
|
| 31 |
彭小雪，郭文婷，马涛，等．肌萎缩侧索硬化认知功能及行为障碍的研究进展[J]．中国神经精神疾病杂志，2018，44(9):562-565.
|
| 32 |
刘文秀，黄旭升．肌萎缩侧索硬化的感觉神经损害[J]．中华神经科杂志，2017，50(3):235-238.
|
| 33 |
Lillo P, Mioshi E, Zoing MC，et al.How common are behavioural changes in amyotrophic lateral sclerosis？[J]．Amyotroph Lateral Scler，2011，12(1):45-51.
|
| 34 |
Goldstein LH, Abrahams S．Changes in cognition and behaviour in amyotrophic lateral sclerosis：nature of impairment and implications for assessment[J]．Lancet Neurol，2013，12(4):368-380.
|
| 35 |
陈慧丰，姚源蓉．肌萎缩侧索硬化症的非典型临床表现研究进展[J]．中华神经医学杂志，2018，17(1):53-56.
|
| 36 |
Kiernan MC, Vucic S, Cheah BC，et al.Amyotrophic lateral sclerosis[J]．Lancet，2011，377(9769):942-955.
|
| 37 |
Hanby MF, Scott KM, Scotton W，et al.The risk to relatives of patients with sporadic amyotrophic lateral sclerosis[J]．Brain，2011，134(Pt 12):3454-3457.
|
| 38 |
National Institute of Neurological Disorders and Stroke(NINDS)．Amyotrophic Lateral Sclerosis(ALS) Fact Sheett[EB/OL]．(2018-08-09)[2019-01-14]．
URL
|
| 39 |
van Es MA, Hardiman O, Chio A，et al.Amyotrophic lateral sclerosis[J]．Lancet，2017，390(10107):2084-2098.
|
| 40 |
郭永强，李森，张海鸿，等．肌萎缩侧索硬化发病机制的研究进展[J]．中国康复理论与实践，2017，23(6):685-689.
|
| 41 |
董高磊，赵宇．肌萎缩性侧索硬化的研究进展[J]．医学综述，2018，24(13):2632-2635,2640.
|
| 42 |
Yamashita S, Ando Y．Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis[J]．Transl Neurodegener，2015，4(1):13.
|
| 43 |
Renton AE, Adriano Chiò A, Traynor BJ.State of play in amyotrophic lateral sclerosis genetics[J]．Nat Neurosci，2014，17(1):17-23.
|
| 44 |
陈嬿，董漪，卢家红，等．中国华东地区家族性肌萎缩侧索硬化症患者SOD1基因突变检测及临床特点分析[J]．中国临床神经科学，2016，24(2):146-152.
|
| 45 |
White MA, Sreedharan J．Amyotrophic lateral sclerosis：recent genetic highlights[J]．Curr Opin Neurol，2016，29(5):557-564.
|
| 46 |
Zufiría M, Gil-Bea FJ, Fernández-Torrón R，et al.ALS：A bucket of genes，environment，metabolism and unknown ingredients[J]．Prog Neurobiol，2016，142:104-129.
|
| 47 |
Therrien M, Dion PA, Rouleau GA.ALS：Recent Developments from Genetics Studies[J]．Curr Neurol Neurosci Rep，2016，16(6):59.
|
| 48 |
Sabatelli M, Marangi G, Conte A，et al.New ALS-related genes expand the spectrum paradigm of amyotrophic lateral sclerosis[J]．Brain Pathol，2016，26(2):266-275.
|
| 49 |
Khairoalsindi OA, Abuzinadah AR.Maximizing the survival of amyotrophic lateral sclerosis patients：current perspectives[J]．Neurol Res Int，2018，2018:1-12.
|
| 50 |
张航，陈思宇，黄旭升．肌萎缩侧索硬化的遗传学研究进展[J]．中华神经科杂志，2017，50(11):867-870.
|
| 51 |
宋彬彬，李阔，徐畅，等．VAPB与肌萎缩侧索硬化症[J]．脑与神经疾病杂志，2018，26(9):587-592.
|
| 52 |
Mayada H, Neda M, Bita S，et al.Clinical presentation and natural history of infantile-onset ascending spastic paralysis from three families with an ALS2 founder variant[J]．Neurol Sci，2018，39(11):1917-1925.
|
| 53 |
Sato K, Otomo A, Ueda MT，et al.Altered oligomeric states in pathogenic ALS2 variants associated with juvenile motor neuron diseases cause loss of ALS2-mediated endosomal function[J]．J Biol Chem，2018，293(44):17135-17153.
|
| 54 |
牛艳芳，熊慧玲，邬剑军，等．肌萎缩侧索硬化患者SOD1基因突变检测及突变与临床表型的关系[J]．遗传，2011，33(7):720-724.
|
| 55 |
Zou ZY, Peng Y, Wang XN，et al.Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin[J]．Neurobiol Aging，2012，33(9):2229.e11-18.
|
| 56 |
Zou ZY, Li XG, Liu MS，et al.Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients[J]．Neurobiol Aging，2013，34(6):1710.e5-6.
|
| 57 |
He J, Tang L, Benyamin B，et al.C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis[J]．Neurobiol Aging，2015，36(9):2660.e1-8.
|
| 58 |
Chen Y, Zheng ZZ, Chen X，et al.SQSTM1 mutations in Han Chinese populations with sporadic amyotrophic lateral sclerosis[J]．Neurobiol Aging，2014，35(3):726.e7-9.
|
| 59 |
Li C, Ji Y, Tang L，et al.Optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in China[J]．Amyotroph Lateral Scler Frontotemporal Degener，2015，16(7-8):485-489.
|
| 60 |
Shu S, Li XL, Liu Q，et al.Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin[J]．Amyotroph Lateral Scler Frontotemporal Degener，2016，17(7-8):605-607.
|
| 61 |
Naruse H, IshiuraH, Mitsui J，et al.Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation[J]．Neurobiol Aging，2018，61:255.e9-16.
|
| 62 |
黄旭升，崔丽英，李晓光，等．第28届国际肌萎缩侧索硬化-运动神经元病会议简介[J]．中华神经科杂志，2018，51(11):932-936.
|
| 63 |
幸伟芳，洪铭范．锌指蛋白512B基因变异的肌萎缩侧索硬化1例报告[J]．中国实用神经疾病杂志，2018，21(15):1729-1732.
|
| 64 |
张航，梁加龙，陈思宇，等．中国人群散发性肌萎缩侧索硬化SETX基因突变筛查[J]．中华医学杂志，2018，98(33):2628-2631.
|
| 65 |
Zhao M, Kim JR, van Bruggen R，et al.RNA-binding proteins in amyotrophic lateral sclerosis[J]．Mol Cells，2018，41(9):818-829.
|
| 66 |
Fosheng H, Stephanie S, Charles F，et al.Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria[J]．eLife，2018，7.
|
| 67 |
Sato K, Otomo A, Ueda MT，et al.Altered oligomeric states in pathogenic ALS2 variants associated with juvenile motor neuron diseases cause loss of ALS2-mediated endosomal function[J]．J Biol Chem，2018，293(44):17135-17153.
|
| 68 |
Clement, AM.Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice[J]．Science，2003，302(5642):113-117.
|
| 69 |
Chen Y, Zhou Q, Gu X，et al.An association study between SCFD1 rs10139154 variant and amyotrophiclateralsclerosisin a Chinese cohort[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(5-6):413-418.
|
| 70 |
Zhou Q, Chen Y, Wei Q，et al.Mutation screening of the CHCHD10 gene in Chinese patients with amyotrophic lateral sclerosis[J]．Mol Neurobiol，2017，54(5):3189-3194.
|
| 71 |
Zondler L, Feiler MS, Freischmidt A，et al.Impaired activation of ALS monocytes by exosomes[J]．Immunol Cell Biol，2017，95(2):207-214.
|
| 72 |
Oeckl P, Weydt P, Steinacker P，et al.Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase[J]．J Neurol Neurosurg Psychiatry，2019，90(1):4-10.
|
| 73 |
Liberman AC, Trias E, da Silva Chagas L，et al.Neuroimmune and inflammatory signals in complex disorders of the central nervous system[J]．Neuroimmunomodulation，2018，5:1-25
|
| 74 |
Gagliardi S, Zucca S, Pandini C，et al.Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients[J]．Scientific Reports，2018，8(1):2378.
|
| 75 |
Lee YB, Baskaran P, Gomez J，et al.C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity[J]．Hum Mol Genet，2017，26(24):4765-4777.
|
| 76 |
Panchal K, Tiwari AK.Mitochondrial dynamics，a key executioner in neurodegenerative diseases[J]．Mitochondrion，2018，S1567-7249(18):30120-X.
|
| 77 |
甘卫明，徐仁伵．帕金森病与肌萎缩侧索硬化发病机制的共性研究[J]．中国老年学杂志，2017，37(7):1818-1820.
|
| 78 |
Machamer JB, Woolums BM, Fuller G，et al.FUS causes synaptic hyperexcitability in Drosophila dendritic arborization neurons[J]．Brain Res，2018，1693(Pt A):55-66.
|
| 79 |
Howells J, Matamala JM, Park SB，et al.In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis[J]．J Physiol，2018，596(22):5379-5396.
|
| 80 |
Bradley WG, Miller RX, Levine TD，et al.Studies of environmental risk factors in amyotrophic lateral sclerosis(ALS) and a phase i clinical trial of i -serine[J]．Neurotoxicity Research，2018，33(1):192-198.
|
| 81 |
Branca JJV, Morucci G, Pacini A．Cadmium-induced neurotoxicity：still much ado[J]．Neural Regen Res，2018，13(11):1879-1882.
|
| 82 |
Vinceti M, Ballotari P, Steinmaus C，et al.Long-term mortality patterns in a residential cohort exposed to inorganic selenium in drinking water[J]．Environmental Res，2016，150:348-356.
|
| 83 |
Oggiano R, Solinas G, Forte G，et al.Trace elements in ALS patients and their relationships with clinical severity[J]．Chemosphere，2018，197:457-466.
|
| 84 |
Vinceti M, Filippini T, Mandrioli J，et al.Lead，cadmium and mercury in cerebrospinal fluid and risk of amyotrophic lateral sclerosis：A case-control study[J]．J Trace Elem Med Biol，2017，43:121-125.
|
| 85 |
Torbick N, Ziniti B, Stommel E，et al.Assessingcyanobacterial harmful algal blooms as risk factors for amyotrophic lateral sclerosis[J]．Neurotox Res，2018，33(1):1-14.
|
| 86 |
Facciponte DN, Bough MW, Seidler D，et al.Identifying aerosolized cyanobacteria in the human respiratory tract：A proposed mechanism for cyanotoxin-associated diseases[J]．Sci Total Environ，2018，645:1003-1013.
|
| 87 |
Gunnarsson LG, Bodin L．Amyotrophic lateral sclerosis and occupational exposures：a systematic literature review and meta-analyses[J]．Int J Environ Res Public Health，2018，15(11):2371.
|
| 88 |
Dickerson AS, Hansen J, Kioumourtzoglou MA，et al.Study of occupation and amyotrophic lateral sclerosis in a Danish cohort[J]．Occup Environ Med，2018，75(9):630-638.
|
| 89 |
万霞，杨文波，刘小妮，等．生活方式与肌萎缩侧索硬化症发病相关性分析[J]．现代医药卫生，2018，34(14):2139-2144.
|
| 90 |
Joy SL, Lynn GD, Andis K．Unhealthy gut，unhealthy brain：The role of the intestinal microbiota in neurodegenerative diseases[J]．Neurochem Int，2018，120:149-163.
|
| 91 |
Pupillo E, Bianchi E, Chiò A，et al.Amyotrophic lateral sclerosis and food intake[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(3-4):267-274.
|
| 92 |
Pupillo E, Poloni M, Bianchi E，et al.Trauma and amyotrophic lateral sclerosis：a european population-based case-control study from the EURALS consortium[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(1-2):118-125.
|
| 93 |
蒋金泰，蒙婞婞，岑祚洁，等．肌萎缩侧索硬化症危险因素的病例对照研究[J]．广西医科大学学报，2018，35(1):112-115.
|
| 94 |
Gómez-Pinedo U, Galán L, Yañez M，et al.Histological changes in the rat brain and spinal cord following prolonged intracerebroventricular infusion of cerebrospinal fluid from amyotrophic lateral sclerosis patients are similar to those caused by the disease[J]．Neurologia，2018，33(4):211-223.
|
| 95 |
Brooks BR.El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis.Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial " Clinical limits of amyotrophic lateral sclerosis" workshop contributors[J]．J Neurol Sci.1994，124(124):96-107.
|
| 96 |
Brooks BR, Miller RG, Swash M，et al.El Escorial revisited：Revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]．Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders，2000，1(5):293-299.
|
| 97 |
De CM, Dengler R, Eisen A，et al.Electrodiagnostic criteria for diagnosis of ALS[J]．Clin Neurophysiol，2008，119(3):497-503.
|
| 98 |
中华医学会神经病学分会肌电图与临床神经电生理学组，中华医学会神经病学分会神经肌肉病学组．中国肌萎缩侧索硬化诊断和治疗指南[J]．中华神经科杂志，2012，45(7):531-533.
|
| 99 |
中华医学会神经病学分会．肌萎缩侧索硬化的诊断标准(草案)[J]．中华神经科杂志，2001，34(3):190-190.
|
| 100 |
Burman R, Wijesekera L, Leigh P，et al.A proposed staging system for amyotrophic lateral sclerosis[J]．Brain，2012，135(Pt 3):847-852.
|
| 101 |
拱忠影，臧大维．肌萎缩侧索硬化生物标记物研究的新进展[J]．中华老年心脑血管病杂志，2017，19(3):330-333.
|
| 102 |
冼珊，邱嘉茗，谢欢欢，等．肌电图对肌萎缩侧索硬化症的早期诊断价值[J]．现代电生理学杂志，2018，25(1):6-8.
|
| 103 |
秦星，靳娇婷，胡芳芳，等．肌萎缩侧索硬化症CMAP波幅与ALSFRS-r评分的相关性分析[J]．西安交通大学学报(医学版)，2018，39(5):634-638.
|
| 104 |
党静霞．肌萎缩侧索硬化症临床特征及诊治进展[J]．西安交通大学学报(医学版)，2018，39(5):613-619.
|
| 105 |
党静霞，胡芳芳，靳娇婷．肌萎缩侧索硬化症的重复电刺激研究[J]．西安交通大学学报(医学版)，2015，(2):235-241.
|
| 106 |
袁宝玉，张金华，沈刚，等．神经生理指数在评估肌萎缩侧索硬化疾病进展速度中的价值[J]．中华神经科杂志，2017，50(11):818-821.
|
| 107 |
Yasuo M, Fumiaki M, Yusuke S，et al.Colocalization of Bunina bodies and TDP-43 inclusions in a case of sporadic amyotrophic lateral sclerosis with Lewy body-like hyaline inclusions[J]．Neuropathology，2018，38(5):521-528.
|
| 108 |
Nakane S, Fujita K, Azuma S，et al.CSF cystatin C and diffusion tensor imaging parameters as biomarkers of upper motor neuron degeneration in amyotrophic lateral sclerosis[J]．Clin Neurol Neurosurg，2018，172:162-168.
|
| 109 |
Watanabe S, Komine O, Endo F，et al.Intracerebroventricular administration of Cystatin C ameliorates disease in SOD1-linked amyotrophic lateral sclerosis mice[J]．J Neurochem，2018，145(1):80-89.
|
| 110 |
Wada Y, Nagai A, Sheikh AM，et al.Co-localization of cystatin C and prosaposin in cultured neurons and in anterior horn neurons with amyotrophic lateral sclerosis[J]．J Neurol Sci，2018，384:67-74.
|
| 111 |
Yu Z, Mi Y, Fangjun L，et al.Aberrant levels of cystatin C in amyotrophic lateral sclerosis：a systematic review and meta analysis[J]．Int J Biol Sci，2018，14(9):1041-1053.
|
| 112 |
俞登虎．脑脊液和血清Cys-C水平在肌萎缩性侧索硬化症患者中的临床价值[J]．国外医学：医学地理分册，2018，39(2):150-155.
|
| 113 |
付洋，马建芳，陈生弟．血清尿酸与神经变性病研究进展[J]．中国现代神经疾病杂志，2018，18(3):204-212.
|
| 114 |
O’Reilly éJ, Bjornevik K, Schwarzschild MA，et al.Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(3-4):194-200.
|
| 115 |
李仁哲，李伶，杨刚毅．TLQP-21研究进展[J]．国际检验医学杂志，2008，29(1):31-32.
|
| 116 |
Christiansen CB, Svendsen B, Holst JJ.The VGF-derived neuropeptide tlqp-21 shows no impact on hormone secretion in the isolated perfused rat pancreas[J]．Horm Metab Res，2015，47(7):537-543.
|
| 117 |
Lin WJ, Jiang C, Sadahiro M，et al.VGF and its c-terminal peptide TLQP-62 regulate memory formation in hippocampus via a BDNF-TrkB-dependent mechanism[J]．J Neurosci，2015，35(28):10343-10356.
|
| 118 |
Brancia C, Noli B, Boido M，et al.TLQP peptides in amyotrophic lateral sclerosis：possible blood biomarkers with a neuroprotective role[J]．Neuroscience，2018，380:152-163.
|
| 119 |
唐迪，常庚，董翔，等．肌萎缩侧索硬化患者血清抗氧化酶水平的临床研究[J]．大连医科大学学报，2018，40(5):438-440.
|
| 120 |
Chen X, Chen Y, Wei Q，et al.Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis[J]．BMC Neurol，2016，16:173.
|
| 121 |
米国霞，李生花．PKCε生物学功能及其在神经系统疾病发生发展中作用机制的研究进展[J]．山东医药，2018，58(43):93-96.
|
| 122 |
Liu ZJ, Lin HX, Liu GL，et al.The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis[J]．Clin Genet，2017，92(3):267-273.
|
| 123 |
张颖，俞春江．ZNF512B基因单核苷酸多态性对肌萎缩侧索硬化患者预后的影响[J]．中华神经医学杂志，2018，17(4):387-391.
|
| 124 |
Placek K, Baer GM, Elman L，et al.UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis[J]．Neurobiol Aging，2019，73:190-199.
|
| 125 |
Piaggio N, Pardini M, Roccatagliata L，et al.Cord cross-sectional area at foramen magnum as a correlate of disability in amyotrophic lateral sclerosis[J]．Eur Radio Exp，2018，2(1):13.
|
| 126 |
Sicong T, Menke RAL, Kevin T，et al.Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis[J]．J Neurol Neurosurg Psychiatry，2018，89(12):1250-1258.
|
| 127 |
Ishaque A, Maani R, Satkunam J，et al.Texture Analysis to Detect Cerebral Degeneration in Amyotrophic Lateral Sclerosis[J]．Can J Neurol Sci，2018，45(5):533-539.
|
| 128 |
Proudfoot M, Van Ede F, Quinn A，et al.Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis[J]．Clin Neurophysiol，2018，129(7):1479-1489.
|
| 129 |
朱文佳，黄旭升．肌萎缩侧索硬化高级神经影像学研究进展[J]．北京医学，2016，38(5):467-470.
|
| 130 |
Agosta F, Spinelli EG, Filippi M．Neuroimaging in amyotrophic lateral sclerosis：current and emerging uses[J]．Expert Rev Neurother，2018，18(5):395-406.
|
| 131 |
王倩楠，张静娜，张晔，等．基于体素形态学和表面形态计量学MRI观察肌萎缩侧索硬化患者大脑结构改变[J]．中国医学影像技术，2018，34(12):1772-1776.
|
| 132 |
Christidi F, Karavasilis E, Riederer F，et al.Gray matter and white matter changes in non-demented amyotrophic lateral sclerosis patients with or without cognitive impairment：A combined voxel-based morphometry and tract-based spatial statistics whole-brain analysis[J]．Brain Imaging Behav，2018，12(2):547-563.
|
| 133 |
Bede P, Hardiman O．Longitudinal structural changes in ALS：a three time-point imaging study of white and gray matter degeneration[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(3-4):232-241.
|
| 134 |
Bao YF, Yang LQ, Chen Y，et al.Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis[J]．Eur Radiol，2018，28(12):4940-4948.
|
| 135 |
Lulé D, Böhm S, Müller HP，et al.Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis[J]．Cortex，2018，101:163-171.
|
| 136 |
Xing F, Prince JL, Stone M，et al.Strain map of the tongue in normal and ALS speech patterns from tagged and diffusion MRI[J]．Proc Spie Int Soc Opt Eng，2018，10574:36.
|
| 137 |
沈东超，侯波，崔博，等．肌萎缩侧索硬化患者认知功能障碍的静息态功能磁共振成像分析[J]．中华医学杂志，2018，98(25):2002-2006.
|
| 138 |
Lautenschläger J, Lautenschläger C, Tadic V，et al.Novel computer vision algorithm for the reliable analysis of organelle morphology in whole cell 3D images — A pilot study for the quantitative evaluation of mitochondrial fragmentation in amyotrophic lateral sclerosis[J]．Mitochondrion，2015，25:49-59.
|
| 139 |
Johansson MT, Ellegaard HR, Tankisi H，et al.Fasciculations in nerve and muscle disorders—a prospective study of muscle ultrasound compared to electromyography[J]．Clin Neurophysiol，2017，128(11):2250-2257.
|
| 140 |
Mah JK, Van Alfen N．Neuromuscular ultrasound：clinical applications and diagnostic values[J]．Can J Neurol Sci，2018，45(6):605-619.
|
| 141 |
Pillen S, Arts IM, Zwarts MJ.Muscle ultrasound in neuromuscular disorders[J]．Muscle Nerve，2010，37(6):679-693.
|
| 142 |
宋彬彬，王清，宋秋萍，等．C型突触终扣与运动神经元病[J]．神经损伤与功能重建，2018，13(3):153-155,158.
|
| 143 |
Rosen AD.Amyotrophic lateral sclerosis.Clinical featuresand prognosis[J]．Arch Neurol，1978，35(10):638-642.
|
| 144 |
Chio A, Mora G, Calvo A，et al.Epidemiology of ALSin Italy：a 10-year prospective population-based study[J]．Neurology，2009，72(8):725-731.
|
| 145 |
贾蕊，靳娇婷，胡芳芳，等.221例散发型肌萎缩侧索硬化症的临床特征[J]．西安交通大学学报(医学版)，2018，39(5):624-628.
|
| 146 |
EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S，et al.EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force[J]．Eur J Neurol，2012，19(3):360-375.
|
| 147 |
Cedarbaum JM, Stambler N, Malta E，et al.The ALSFRS-R：a revised ALS functional rating scale that incorporates assessments of respiratory function.BDNF ALS Study Group(Phase III)[J]．Journal of the Neurological Sciences，1999，169(1-2):13-21.
|
| 148 |
Lee M, McCambridge A．Clinimetrics：Amyotrophic Lateral Sclerosis Functional Rating Scale-revised(ALSFRS-R)[J]．J Physiother 2018，64(4):269-270.
|
| 149 |
Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT，et al.Early symptom progression rate is related to ALS outcome：a prospective population based study[J]．Neurology，2002，59:99-103.
|
| 150 |
Gomeni R, Fava M．Amyotrophic lateral sclerosis disease progression model[J]．Amyotrophic Lateral Sclerosis Frontotemporal Degener，2014，15(1-2):119-129.
|
| 151 |
Gordon PH, Cheung YK.Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS[J]．Neurology，2006，66(7):1314-1315.
|
| 152 |
Proudfoot M, Jones A, Talbot K，et al.The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset[J]．Amyotroph Lateral Scler Frontotemporal Degener，2016，17(5-6):414-425.
|
| 153 |
郑勇，臧大维．肌萎缩性侧索硬化患者粒细胞集落刺激因子的水平[J]．广东医学，2017，38(18):2806-2809.
|
| 154 |
靳娇婷，胡芳芳，秦星，等．肌萎缩侧索硬化症患者执行功能损害的量表优化[J]．西安交通大学学报(医学版)，2018，39(5):629-633.
|
| 155 |
李栩琳，杨婉琪，王贵彬，等．肌萎缩侧索硬化症治疗药物研发进展[J]．中国药理学与毒理学杂志，2018，32(3):223-232.
|
| 156 |
Lazarevic V, Yang Y, Ivanova D，et al.Riluzoleattenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool[J]．Neuropharmacology，2018，143:38-48.
|
| 157 |
Lu C, Xiaolu L, Lu T，et al.Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients：a real-world cohort study in China[J]．Front Aging Neurosci，2016，8:246.
|
| 158 |
Lemieszek MK, Stepulak A, Sawa-Wejksza K，et al.Riluzole inhibits proliferation，migration and cell cycle progression and induces apoptosis in tumor cells of various origins[J]．Anticancer Agents Med Chem，2018，18(4):565-572.
|
| 159 |
Ahmadi M, Agah E, Nafissi S，et al.Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis：a pilot randomized clinical trial[J]．Neurotherapeutics，2018，15(2):430-438.
|
| 160 |
Shibata N, Kawaguchi-Niida M, Yamamoto T，et al.Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis[J]．Neuropathology，2008，28(4):387-398.
|
| 161 |
Schutz, B.The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice[J]．J Neurosci，2005，25(34):7805-7812.
|
| 162 |
Kiaei M, Kipiani K, Chen J，et al.Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis[J]．Exp Neurol，2005，191(2):331-336.
|
| 163 |
Luc D, Reinhard D, Heneka MT，et al.A randomized，double blind，placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis[J]．PLoS ONE，2012，7(6):e37885.
|
| 164 |
Kim S, Kim JK, Son MJ，et al.Mecasin treatment in patients with amyotrophic lateral sclerosis：study protocol for a randomized controlled trial[J]．Trials，2018，19(1):225.
|
| 165 |
Brooks BR, Jorgenson JA, Newhouse BJ，et al.Edaravone in the treatment of amyotrophic lateral sclerosis：efficacy and access to therapy - a roundtable discussion[J]．Am J Manag Care，2018，24(9 Suppl):S175.
|
| 166 |
Masamitsu O, Satoshi Y, Hidetsugu U，et al.Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis[J]．eNeurologicalSci，2018，11:11-14.
|
| 167 |
Wang J, Chen X, Yuan B，et al.Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers[J]．Clin Ther，2018，40(10):1683-1691.
|
| 168 |
Luo L, Song Z, Li X，et al.Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis[J]．Neurol Sci，2018 Nov.
|
| 169 |
Trias E, Ibarburu S, Barreto-Núñez R，et al.Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis[J]．J Neuroinflam，2016，13(1):177.
|
| 170 |
Salvado M．Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient[J]．World J Gastroenterol，2015，21(36):10475-1049.
|
| 171 |
Hwee DT, Adam K, Julie R，et al.Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model[J]．PLoS ONE，2014，9(5):e96921.
|
| 172 |
Shefner JM, Wolff AA, Meng L．The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS[J]．Amyotroph Lateral Scler Frontotemporal Degener，2013，14(7-8):582-585.
|
| 173 |
Shefner JM, Watson ML, Meng L，et al.A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis[J]．Amyotroph Lateral Scler Frontotemporal Degener，2013，14(7-8):574-581.
|
| 174 |
Andrews JA, Cudkowicz ME, Hardiman O，et al.VITALITY-ALS，a phase III trial of tirasemtiv，a selective fast skeletal muscle troponin activator，as a potential treatment for patients with amyotrophic lateral sclerosis：study design and baseline characteristics[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018，19(3-4):259-266.
|
| 175 |
黄世杰．医药信息[J]．国际药学研究杂志，2016，43(5):1008-1008.
|
| 176 |
Dunlop RA, Cox PA, Banack SA，et al.The non-protein amino acid bmaa is misincorporated into human proteins in place of l-serine causing protein misfolding and aggregation[J]．PLOS ONE，2013，8(9):e75376.
|
| 177 |
Cox PA, Davis DA, Mash DC，et al.Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain[J]．Proc Biol Sci，2016，283(1823):20152397.
|
| 178 |
Metcalf JS, Dunlop RA, Powell JT，et al.L-serine：a naturally-occurring amino acid with therapeutic potential[J]．Neurotox Res，2018，33(1):213-221.
|
| 179 |
Main BJ, DunlopRA, Rodgers KJ.The use of L-serine to prevent β-methylamino-L-alanine(BMAA)-induced proteotoxic stress in vitro[J]．Toxicon，2016，109:7-12.
|
| 180 |
Kovalchuk MO, Heuberger JA, Sleutjes BT，et al.Acute effects of riluzole and retigabine on axonal excitability in patients with ALS：A randomized，double-blind，placebo-controlled，cross-over trial[J]．Clin Pharmacol Ther，2018，104(6):1136-1145.
|
| 181 |
Parakh S, Jagaraj CJ, Vidal M，et al.ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis[J]．Hum Mol Genet，2018，27(8):1311-1331.
|
| 182 |
Nicaise C, Coupier J, Dabadie MP，et al.Gemals，a new drug candidate，extends lifespan and improves electromyographic parameters in a rat model of amyotrophic lateral sclerosis[J]．Amyotroph Lateral Scler，2008，9(2):85-90.
|
| 183 |
Geffard M, Mangas A, Bedat D，et al.GEMALS：A promising therapy for amyotrophic lateral sclerosis[J]．Exp Ther Med，2018，15(4):3203-3210.
|
| 184 |
Kaufmann P, Thompson JLP, Levy G，et al.Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III[J]．Ann Neurol，2009，66(2):235-244.
|
| 185 |
王坤，王舒，刘珊，等．丁苯酞对SOD1G93A转基因鼠脊髓Ferritin表达的影响[J]．脑与神经疾病杂志，2014，22(1):19-22.
|
| 186 |
孙灿，闫欣，郝澎丽，等．丁苯酞对肌萎缩侧索硬化模型小鼠的生存期脊髓前角运动神经元Nrf2及HO-1表达[J]．脑与神经疾病杂志，2016，24(3):136-141.
|
| 187 |
王舒，刘亚玲，孙灿，等．丁苯酞单独或联合应用利鲁唑对hSOD1G93A转基因小鼠影响[J]．脑与神经疾病杂志，2015，(6):408-412.
|
| 188 |
冯新红，袁伟，彭英，等．丁基苯酞对肌萎缩侧索硬化转基因小鼠神经保护作用的初步探讨[J]．中国神经免疫学和神经病学杂志，2013，20(1):20-23.
|
| 189 |
石药集团恩必普药业有限公司．一种含有丁苯酞的药物组合物及其在治疗ALS病药物中的应用：中国，CN201610546425.1[P].2018-01-19.
|
| 190 |
岳茂兴，周培根，郝冬琳，等．一种促进神经损伤修复的药物组合物治疗22例ALS患者1年后的疗效观察[J/CD]．中华卫生应急电子杂志，2018，4(5):264-272.
|
| 191 |
岳茂兴，周培根，郝冬琳，等．一种促进神经损伤修复的药物组合物治疗60例MND患者6个月后的疗效观察[J/CD]．中华卫生应急电子杂志，2018，4(5):281-289.
|
| 192 |
岳茂兴，周培根，郝冬琳，等．中西医结合创新治疗运动神经元病286例报告[J/CD]．中华卫生应急电子杂志，2018，4(5):273-280.
|
| 193 |
岳茂兴，周培根，郝冬琳，等．典型病例中西医结合创新疗法治疗运动神经元病7例典型病例报告[J/CD]．中华卫生应急电子杂志，2018，4(5):317-320.
|
| 194 |
尹进南，岳茂兴，冯斌，等．运动神经元病的综合管理[J/CD]．中华卫生应急电子杂志，2018，4(5):302-305.
|
| 195 |
钱亿超，岳茂兴，杨学峰，等.302例运动神经元病临床护理效果探讨[J/CD]．中华卫生应急电子杂志，2018，4(5):308-310.
|
| 196 |
Ly CV, Miller TM.Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis[J]．Curr Opin Neurol，2018，31(5):648-654.
|
| 197 |
Wen D, Cui C, Duan W，et al.The role of insulin-like growth factor 1 in ALS cellandmouse models：A mitochondrial protector[J]．Brain Res Bull，2019，144:1-13.
|
| 198 |
Wang W, Wen D, Duan W，et al.Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway[J]．Brain Res Bull，2018，05(139):203-210.
|
| 199 |
Wang Y, Liu Y, Zhai J，et al.scAAV9-VEGF-165 inhibits neuroinflammatory response and invasion of macrophages into the peripheral nervous system of ALS transgenic mice[J]．Brain Res Bull，2018，140:233-242.
|
| 200 |
Asheuer M, Pflumio F, Benhamida S，et al.Human CD34＋ cells differentiate into microglia and express recombinant therapeutic protein[J]．Proc Natl Acad Sci U S A，2004，101(10):3557-3562.
|
| 201 |
Glass JD, Boulis NM, Johe K，et al.Lumbar Intraspinal Injection of Neural Stem Cells in Patients with Amyotrophic Lateral Sclerosis：Results of a Phase I Trial in 12 Patients[J]．Stem Cells，2012，30(6):1144-1151.
|
| 202 |
Baloh RH, Glass JD, Svendsen CN.Stemceltransplantation for amyotrophic lateral sclerosis[J]．Curr Opin Neurol，2018，31(5):655-661.
|
| 203 |
吴焕童，赵宇，张淑萍，等．间充质干细胞在神经退行性疾病治疗中的应用进展[J]．山东医药，2018，58(11):102-104.
|
| 204 |
Atassi N, Beghi E, Blanquer M，et al.Intraspinal stem cell transplantation for amyotrophic lateral sclerosis：Ready for efficacy clinical trials？[J]．Ann Neurol，2016，18(12):1471-1475.
|
| 205 |
Squires A, Oshinski JN, Boulis NM，et al.SpinoBot：an MRI-guided needle positioning system for spinal cellular therapeutics[J]．Ann Biomed Eng，2018，46(3):475-487.
|
| 206 |
汪双双，杨晓军．邓铁涛教授治疗肌萎缩侧索硬化症经验整理[J]．广州中医药大学学报，2017，27(3):310-312.
|
| 207 |
曹利民，张清奇，裘昌林．裘昌林教授辨识舌象论治肌萎缩侧索硬化临床用药经验[J]．中国现代医生，2017，55(2):112-115.
|
| 208 |
王安琦，李秀兰，任展能，等．健脾益肺法治疗肌萎缩侧索硬化的疗效研究[J]．世界中医药，2017，12(6):1364-1367.
|
| 209 |
邱连利．伊达伟老师治疗痿证的经验[J]．甘肃中医学院学报，2005，22(2):3-4.
|
| 210 |
周诗远，石学敏．醒脑开窍法治疗肌萎缩侧索硬化验案1则[J]．湖南中医杂志，2017，33(9):116-117.
|
| 211 |
赵立杰，陈新华，李笑男．温针灸治疗运动神经元病疗效观察[c].2013中国针灸学会学术年会一第四届中医药现代化国际科技大会针灸研究与国际化分会论文集，2013：1.
|
| 212 |
李晓艳，刘明杰，尹安春，等．中药补益类方药治疗肌萎缩侧索硬化症的Meta分析[J]．中国实验方剂学杂志，2016，22(4):201-207.
|
| 213 |
郭颖，祝鹏宇，孙颖哲，等．夹脊电针对ALS-SOD1-G93A转基因小鼠腰髓前角运动神经元形态学的影响[J]．针灸临床杂志，2017，33(5):60-64.
|
| 214 |
巫遥．强肾健脾法治疗运动神经元病的临床疗效观察[D]．南京：南京中医大学，2015.
|
| 215 |
许浩游，王安琦，侯晓妹，等．高压氧在治疗肌萎缩侧索硬化中的应用[J]．广东医学，2014，35(5):702-703.
|
| 216 |
杜宝新，许浩游，赵晶，等．高压氧治疗30例肌萎缩侧索硬化患者疗效观察[C]．//中华医学会第二十一次全国高压氧医学学术会议论文集，2012：259-261.
|
| 217 |
Dupuis L, Oudart H, René F，et al.Evidence for defective energy homeostasis in amyotrophic lateral sclerosis：benefit of a high-energy diet in a transgenic mouse model[J]．Proc Natl Acad Sci U S A，2004，101(30):11159-11164.
|
| 218 |
Paganoni S, Deng J, Jaffa M，et al.Body mass index，not dyslipidemia，is an independent predictor of survival in amyotrophic lateral sclerosis[J]．Muscle & Nerve，2011，44(1):20-24.
|
| 219 |
Dupuis L, Corcia P, Fergani A，et al.Dyslipidemia is a protective factor in amyotrophic lateral sclerosis[J]．Neurology，2008，70(13):1004.
|
| 220 |
Dorst J, Kühnlein P, Hendrich C，et al.Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis[J]．J Neurol，2011，258(4):613-617.
|
| 221 |
D’Ovidio F, d’Errico A, Carnà P，et al.The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis[J]．Eur J Neurol，2018，25(1):164-170.
|
| 222 |
傅小玲，朱文佳，舒刚明，等．肌萎缩侧索硬化患者心理健康状况与影响因素分析[J]．北京医学，2016，38(5):417-420.
|
| 223 |
Guy V, Soriani MH, Bruno M，et al.Brain computer interface with the P300 speller：Usability for disabled people with amyotrophic lateral sclerosis[J]．Ann Phys Rehabil Med，2018，61(1):5-11.
|
| 224 |
Harrison D, Mehta P, van Es MA，et al. "ALS reversals" ：demographics，disease characteristics，treatments，and co-morbidities[J]．Amyotroph Lateral Scler Frontotemporal Degener，2018:1-5.
|
| 225 |
Bonaventura G, Iemmolo R, D’Amico AG，et al.PACAP and PAC1R are differentially expressed in motor cortex of amyotrophic lateral sclerosis patients and support survival of iPSC-derived motor neurons[J]．J Cell Physiol，2018，233(4):3343-3351.
|
| 226 |
Daniel H, Richard B．ALS Reversals：Demographics，Disease Characteristics，Treatments and Co-Morbidities(P3.135)[J]．Neurology，2017，88(16 Supplement):P3.135.
|
| 227 |
Morrice JR, Gregory-Evans CY, ShawCA.Animal models of amyotrophic lateral sclerosis：A comparison of model validity[J]．Neural Regen Res，2018，13(12):2050-2054.
|
| 228 |
Endo K, Ishigaki S, Masamizu Y，et al.Silencing of FUS in the common marmoset(Callithrix jacchus) brain via stereotaxic injection of an adeno-associated virus encoding shRNA[J]．Neurosci Res，2018，130:56-64.
|
| 229 |
Liu C, Hong K, Chen H，et al.Evidence for a protective role of CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis[J]．Biol Chem，2018 Oct.
|